Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operating and Financial Condition. |
We are furnishing this Item 2.02 in connection with the
disclosure of information, in the form of the textual information
from a press release on May 9, 2017 entitled Xtant Medical
Reports First Quarter Revenue of $22.1 million, 5% Growth
Compared to Prior Year Period and attached as Exhibit 99.1
hereto.
The information in this Item 2.02 (including Exhibit 99.1 hereto)
is being furnished to Item 2.02 and shall not be deemed to be
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of
that section.
We do not have, and expressly disclaim, any obligation to release
publicly any updates or any changes in our expectations or any
change in events, conditions, or circumstances on which any
forward-looking statement is based.
The text included with this report is available on our website
located at www.xtantmedical.com, however the contents of
our website are not incorporated by reference herein.
This Form 8-K contains forward-looking statements that are
subject to various assumptions, risks and uncertainties. These
forward-looking statements may include financial projections,
revenue and earnings guidance and other statements or assumptions
regarding our expectations and beliefs. The Company believes that
its expectations, as expressed in these statements are based on
reasonable assumptions regarding the risks and uncertainties
inherent in achieving those expectations. These statements are
not, however, guarantees of performance and actual results may
differ materially. Risks and uncertainties which may cause actual
results to be different than expressed or implied in our
forward-looking statements include, but are not limited to, the
risk factors described under the heading Risk Factors in our
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
The Company expressly disclaims any current intention to update
any forward-looking statements as a result of new information or
future events or developments.
| Item 7.01 | Regulation FD Disclosure. |
As disclosed in Item 2.02 above, the Company issued a press
release on May 9, 2017 entitled Xtant Medical Reports First
Quarter Revenue of $22.1 million, 5% Growth Compared to Prior
Year Period and attached as Exhibit 99.1 hereto. Under the
heading Outlook for Full Year 2017, the Company disclosed that
[a]s a result of its ongoing review of its capital structure, the
Company has made a decision to withdraw its previously provided
2017 financial guidance. The company will provide an update to
shareholders once the review and related discussions have been
finalized.
The information in this Item 7.01 and the document attached as
Exhibit 99.1 are being furnished and shall not be deemed filed
for purposes of Section 18 of the Securities and Exchange Act of
1934, as amended (the Exchange Act), nor otherwise subject
to the liabilities of that section, nor incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description | |
| 99.1 |
Press Release dated May 9, 2017 entitled Xtant Medical Reports First Quarter Revenue of $22.1 million, 5% Growth Compared to Prior Year Period |
About Xtant Medical Holdings, Inc. (NYSEMKT:XTNT)
Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications. Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Recent Trading Information
Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) closed its last trading session down -0.038 at 0.433 with 332,444 shares trading hands.
